Jim O'Neill Optimistic His AMR Review Won't Run Into The Sand
This article was originally published in Scrip
Executive Summary
Jim O'Neill says he spends sleepless nights worrying whether his Review of Antimicrobial Resistance (AMR) will run out of steam once completed in two months' time – but he's encouraged by growing evidence world leaders and the pharma industry are seriously embracing the theme and will soon make lasting commitments to effectively combat antibiotic resistance.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.